Cyrano Therapeutics has been prominently featured in Clinical Trial Vanguard for its pioneering work in treating long-term smell loss, to restore the sense of smell, with the FLAVOR clinical trial.
The article profiles Cyrano’s innovative intranasal therapy, CYR-064, which is currently being studied as the first pharmaceutical intervention for post-viral olfactory loss (PVOL) to restore the sense of smell.
Led by CEO and co-founder Rick Geoffrion, Cyrano Therapeutics is at the forefront of restoring smell and flavor perception in patients impacted by persistent sensory loss following viral infections such as COVID-19. The FLAVOR trial reflects a major step forward in addressing an often-overlooked medical condition that affects millions globally.
The feature explores Cyrano’s scientific strategy and the critical importance of sensory recovery—not just for enjoyment of life, but also for safety and overall well-being. With no approved pharmaceutical treatments currently available for PVOL, CYR-064 represents a new category of therapeutic innovation that redefines how the industry approaches sensory endpoints in clinical care.
Read the full article here → First Pharma to Restore the Sense of Smell? Inside the FLAVOR Trial Quest to Treat Postviral Olfactory Loss